rpl-11.1 Antibody

Biological Role of RPL-11.1

RPL-11.1 is a ribosomal protein involved in ribosome assembly and nucleolar dynamics. Studies in C. elegans demonstrate its role in longevity:

• Nucleolar Size Regulation: Silencing rpl-11.1 reduces nucleolar size, a biomarker of extended lifespan .

• Autophagy Interaction: RPL-11.1 degradation via the autophagy protein LGG-1 enhances proteostasis and lifespan in daf-2 mutants .

• Neuroprotection: rpl-11.1 knockdown rescues β-amyloid–expressing nematodes from paralysis, suggesting therapeutic potential in neurodegeneration .

In humans, RPL11 (the ortholog) stabilizes p53 by binding MDM2, inhibiting its ubiquitin ligase activity during nucleolar stress . This pathway is conserved across species, highlighting RPL-11.1/RPL11’s role in stress responses.

Research Applications of RPL-Antibodies

While specific C. elegans rpl-11.1 antibodies are not commercially detailed, human RPL11 antibodies (targeting the homologous protein) are widely used. Key applications include:

Key Research Findings Using RPL-11/RPL-Antibodies

• p53 Regulation: RPL11 binds MDM2, stabilizing p53 during ribosomal stress (e.g., actinomycin D treatment) . Depleting RPL11 reduces p53 activation .

• Mutual Protection: RPL5 and RPL11 stabilize each other in ribosome-free states, preventing proteasomal degradation .

• GRWD1 Interaction: GRWD1 competes with MDM2 for RPL11 binding, modulating p53 levels and oncogenic transformation .

Implications for Disease

• Cancer: RPL11 acts as a tumor suppressor by stabilizing p53. Dysregulation is linked to ribosomopathies like Diamond-Blackfan anemia .

• Neurodegeneration: Modulating RPL-11.1 levels improves outcomes in β-amyloid models, suggesting therapeutic targeting .

Limitations and Future Directions

• Species-specific antibodies for C. elegans rpl-11.1 remain underdeveloped compared to human RPL11 tools.

• Further studies are needed to clarify RPL-11.1’s role in autophagy-ribosome crosstalk and its potential in age-related diseases.